Education
About Us
Working with TipRanks
Follow Us
Werewolf Therapeutics (HOWL)
NASDAQ:HOWL
HOWL Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.60 - $4.18
Previous CloseN/A
Volume113.58K
Average Volume (3M)215.68K
Market Cap
$62.19M
Enterprise Value$8.58M
Total Cash (Recent Filing)$78.49M
Total Debt (Recent Filing)$10.04M
Price to Earnings (P/E)―
Beta1.68
Next Earnings
Nov 06, 2025EPS Estimate
-0.39Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.40
Shares Outstanding45,729,000
10 Day Avg. Volume156,013
30 Day Avg. Volume215,684
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.14
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-3.81
Enterprise Value/Ebitda-0.13
Forecast
1Y Price Target
$6.25Price Target Upside369.92% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
Bulls Say, Bears Say
Bulls Say
Clinical ActivityEarly anti-tumor activity was observed in WTX-330 with a confirmed partial response in a metastatic melanoma patient, achieving a 46% reduction in tumor size.
Partnerships And Cash PositionWerewolf represents an interesting investment opportunity with a partnership with Jazz Pharmaceuticals and a cash position of $122.8MM.
Pipeline EvolutionWerewolf's latest update marks a clear step forward in the evolution of its pipeline, with progress across all three of its active programs.
Bears Say
Revenue And ExpensesWerewolf reported no revenues for 4Q24 as expected, and R&D expenses were higher than estimated.
Strategic DirectionIt is unlikely that the new strategic direction with TCE platform will result in significant appreciation for HOWL in the near-term due to its nascent development stage.
Uncertainty In Data OutcomesThere is uncertainty whether the outcomes of WTX-124’s monotherapy and combination trials will be robust enough to engage an investor base generally disinterested in novel cytokine programs.
Werewolf Therapeutics News
HOWL FAQ
What was Werewolf Therapeutics’s price range in the past 12 months?
Werewolf Therapeutics lowest stock price was $0.59 and its highest was $4.18 in the past 12 months.
What is Werewolf Therapeutics’s market cap?
Werewolf Therapeutics’s market cap is $62.19M.
When is Werewolf Therapeutics’s upcoming earnings report date?
Werewolf Therapeutics’s upcoming earnings report date is Nov 06, 2025 which is in 69 days.
How were Werewolf Therapeutics’s earnings last quarter?
Werewolf Therapeutics released its earnings results on Aug 14, 2025. The company reported -$0.4 earnings per share for the quarter, beating the consensus estimate of -$0.468 by $0.068.
Is Werewolf Therapeutics overvalued?
According to Wall Street analysts Werewolf Therapeutics’s price is currently Undervalued.
Does Werewolf Therapeutics pay dividends?
Werewolf Therapeutics does not currently pay dividends.
What is Werewolf Therapeutics’s EPS estimate?
Werewolf Therapeutics’s EPS estimate is -0.39.
How many shares outstanding does Werewolf Therapeutics have?
Werewolf Therapeutics has 45,729,000 shares outstanding.
What happened to Werewolf Therapeutics’s price movement after its last earnings report?
Werewolf Therapeutics reported an EPS of -$0.4 in its last earnings report, beating expectations of -$0.468. Following the earnings report the stock price went down -2.222%.
Which hedge fund is a major shareholder of Werewolf Therapeutics?
Currently, no hedge funds are holding shares in HOWL
Werewolf Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$6.25 (369.92% Upside)
$6.25 (369.92% Upside)
Blogger Sentiment
Bullish
HOWL Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 536.4K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.1%
Last 30 Days ▼ 5.7%
Last 30 Days ▼ 5.7%
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-47.89%
12-Months-Change
Fundamentals
Return on Equity
-100.55%
Trailing 12-Months
Asset Growth
-39.78%
Trailing 12-Months
Company Description
Werewolf Therapeutics
Werewolf Therapeutics, Inc., a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies. Its lead product candidates are WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule for the treatment of advanced solid tumors; and WTX-330, a conditionally activated Interleukin-12 INDUKINE molecule for the treatment of relapsed or refractory advanced or metastatic solid tumors or lymphoma. The company is also developing WTX-613, a conditionally activated interferon alpha INDUKINE molecule for the treatment of solid tumors and hematologic malignancies. Werewolf Therapeutics, Inc. was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.
HOWL Stock 12 Month Forecast
Average Price Target
$6.25
▲(369.92% Upside)
Technical Analysis
Karyopharm Therapeutics
―
Atara Biotherapeutics
―
X4 Pharmaceuticals
―
NRX Pharmaceuticals
―
CAMP4 Therapeutics Corporation
―
Ownership Overview
50.22% Insiders
5.15% Mutual Funds
34.06% Other Institutional Investors
8.03% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---